Stock Track | Disc Medicine Plummets 5.03% Intraday on FDA Setback for Lead Drug Candidate

Stock Track

03/05

Disc Medicine's stock plummeted 5.03% during intraday trading on Wednesday.

The sharp decline follows the company's disclosure that it received a Complete Response Letter from the U.S. Food and Drug Administration for its lead drug candidate, bitopertin. This regulatory action indicates the FDA is not approving the drug at this time.

Additionally, law firm Levi & Korsinsky has opened a securities investigation into Disc Medicine over potential federal securities law violations related to the company's disclosures about the FDA review process for bitopertin.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1127911300"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127911300\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127911300?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 04:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127911300","market":"nz","top_or_hot":-1,"title":"Stock Track | Disc Medicine Plummets 5.03% Intraday on FDA Setback for Lead Drug Candidate","media":"Stock Track","content":"<p>Disc Medicine's stock plummeted 5.03% during intraday trading on Wednesday.</p><p>The sharp decline follows the company's disclosure that it received a Complete Response Letter from the U.S. Food and Drug Administration for its lead drug candidate, bitopertin. This regulatory action indicates the FDA is not approving the drug at this time.</p><p>Additionally, law firm Levi & Korsinsky has opened a securities investigation into Disc Medicine over potential federal securities law violations related to the company's disclosures about the FDA review process for bitopertin.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Disc Medicine Plummets 5.03% Intraday on FDA Setback for Lead Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Disc Medicine Plummets 5.03% Intraday on FDA Setback for Lead Drug Candidate\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-03-05 04:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Disc Medicine's stock plummeted 5.03% during intraday trading on Wednesday.</p><p>The sharp decline follows the company's disclosure that it received a Complete Response Letter from the U.S. Food and Drug Administration for its lead drug candidate, bitopertin. This regulatory action indicates the FDA is not approving the drug at this time.</p><p>Additionally, law firm Levi & Korsinsky has opened a securities investigation into Disc Medicine over potential federal securities law violations related to the company's disclosures about the FDA review process for bitopertin.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRON","symbol_name":"Disc Medicine","start_time":0,"source_url":"","article_id":"1127911300","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127911300","pubTimestamp":1772657558,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Disc Medicine's stock plummeted 5.03% during intraday trading on Wednesday.The sharp decline follows the company's disclosure that it received a Complete Response Letter from the U.S. Food and Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRON":"Disc Medicine"},"translate_title":"个股追踪|迪思医药盘中暴跌5.03%因FDA对主要候选药物受挫","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRON":1},"content_text":"Disc Medicine's stock plummeted 5.03% during intraday trading on Wednesday.The sharp decline follows the company's disclosure that it received a Complete Response Letter from the U.S. Food and Drug Administration for its lead drug candidate, bitopertin. This regulatory action indicates the FDA is not approving the drug at this time.Additionally, law firm Levi & Korsinsky has opened a securities investigation into Disc Medicine over potential federal securities law violations related to the company's disclosures about the FDA review process for bitopertin.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}